Anirban Basu1, Anand Dalal2, Giorgio Walter Canonica3, Mark Forshag4, Steven W Yancey5, Saurabh Nagar6, Christopher F Bell2. 1. a Pharmaceutical Outcomes Research and Policy Program , University of Washington , Seattle , WA , USA. 2. b US Value, Evidence and Outcomes, US Medical Affairs, GlaxoSmithKline , Durham , NC , USA. 3. c Personalized Medicine Asthma & Allergy Clinic Humanitas University, IRCCS-Humanitas Research Hospital , Rozzano-Milano , Italy. 4. d US Medical Affairs, Respiratory Therapeutic Area, GlaxoSmithKline , Durham , NC , USA. 5. e R&D, Respiratory Therapeutic Area Unit, GlaxoSmithKline , Durham , NC , USA. 6. f Health Economics, RTI-Health Solutions , Research Triangle Park , NC , USA.
Abstract
BACKGROUND:Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). METHODS: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. RESULTS:Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. CONCLUSIONS: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723-$840 per patient, differences were not statistically significant.
RCT Entities:
BACKGROUND: Severe eosinophilic asthmapatients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). METHODS: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. RESULTS: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. CONCLUSIONS: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723-$840 per patient, differences were not statistically significant.
Entities:
Keywords:
Cost analysis; eosinophilic phenotype; exacerbation; mepolizumab; severe asthma
Authors: Diego Bagnasco; Massimiliano Povero; Lorenzo Pradelli; Luisa Brussino; Giovanni Rolla; Marco Caminati; Francesco Menzella; Enrico Heffler; Giorgio Walter Canonica; Pierluigi Paggiaro; Gianenrico Senna; Manlio Milanese; Carlo Lombardi; Caterina Bucca; Andrea Manfredi; Rikki Frank Canevari; Giovanni Passalacqua Journal: World Allergy Organ J Date: 2021-01-27 Impact factor: 4.084